OpenURL Connection Search

Select item for more details and to access through your institution.

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
Published in:
International Journal of Molecular Sciences, 2023, v. 24, n. 5, p. 4522, doi. 10.3390/ijms24054522
By:
- Alves, Carla L.;
- Ditzel, Henrik J.
Publication type:
Article
Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer.
Published in:
International Journal of Molecular Sciences, 2022, v. 23, n. 17, p. 10053, doi. 10.3390/ijms231710053
By:
- Skov, Natascha;
- Alves, Carla L.;
- Ehmsen, Sidse;
- Ditzel, Henrik J.
Publication type:
Article
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Published in:
2021
By:
- Alves, Carla L.;
- Ehmsen, Sidse;
- Terp, Mikkel G.;
- Portman, Neil;
- Tuttolomondo, Martina;
- Gammelgaard, Odd L.;
- Hundebøl, Monique F.;
- Kaminska, Kamila;
- Johansen, Lene E.;
- Bak, Martin;
- Honeth, Gabriella;
- Bosch, Ana;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Correction Notice
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Published in:
Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25422-9
By:
- Alves, Carla L.;
- Ehmsen, Sidse;
- Terp, Mikkel G.;
- Portman, Neil;
- Tuttolomondo, Martina;
- Gammelgaard, Odd L.;
- Hundebøl, Monique F.;
- Kaminska, Kamila;
- Johansen, Lene E.;
- Bak, Martin;
- Honeth, Gabriella;
- Bosch, Ana;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Article
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Published in:
Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25422-9
By:
- Alves, Carla L.;
- Ehmsen, Sidse;
- Terp, Mikkel G.;
- Portman, Neil;
- Tuttolomondo, Martina;
- Gammelgaard, Odd L.;
- Hundebøl, Monique F.;
- Kaminska, Kamila;
- Johansen, Lene E.;
- Bak, Martin;
- Honeth, Gabriella;
- Bosch, Ana;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Article
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Published in:
2021
By:
- Kaminska, Kamila;
- Akrap, Nina;
- Staaf, Johan;
- Alves, Carla L.;
- Ehinger, Anna;
- Ebbesson, Anna;
- Hedenfalk, Ingrid;
- Beumers, Lukas;
- Veerla, Srinivas;
- Harbst, Katja;
- Ehmsen, Sidse;
- Borgquist, Signe;
- Borg, Åke;
- Pérez-Fidalgo, Alejandro;
- Ditzel, Henrik J.;
- Bosch, Ana;
- Honeth, Gabriella
Publication type:
journal article
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Published in:
NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-020-00210-8
By:
- Løkkegaard, Sanne;
- Elias, Daniel;
- Alves, Carla L.;
- Bennetzen, Martin V.;
- Lænkholm, Anne-Vibeke;
- Bak, Martin;
- Gjerstorff, Morten F.;
- Johansen, Lene E.;
- Vever, Henriette;
- Bjerre, Christina;
- Kirkegaard, Tove;
- Nordenskjöld, Bo;
- Fornander, Tommy;
- Stål, Olle;
- Lindström, Linda S.;
- Esserman, Laura J.;
- Lykkesfeldt, Anne E.;
- Andersen, Jens S.;
- Leth-Larsen, Rikke;
- Ditzel, Henrik J.
Publication type:
Article
Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies.
Published in:
Cancers, 2021, v. 13, n. 21, p. 5397, doi. 10.3390/cancers13215397
By:
- Al-Qasem, Abeer J.;
- Alves, Carla L.;
- Ditzel, Henrik J.
Publication type:
Article
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Published in:
2018
By:
- Alves, Carla L.;
- Elias, Daniel;
- Lyng, Maria B.;
- Bak, Martin;
- Ditzel, Henrik J.
Publication type:
journal article
Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
Published in:
International Journal of Cancer, 2024, v. 155, n. 12, p. 2211, doi. 10.1002/ijc.35126
By:
- Kindt, Charlotte K.;
- Alves, Carla L.;
- Ehmsen, Sidse;
- Kragh, Amalie;
- Reinert, Thomas;
- Vogsen, Marianne;
- Kodahl, Annette R.;
- Rønlev, Jeanette D.;
- Ardik, Dilan;
- Sørensen, Anna L.;
- Evald, Kirstine;
- Clemmensen, Mia L.;
- Staaf, Johan;
- Ditzel, Henrik J.
Publication type:
Article
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
Published in:
NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00311-6
By:
- Al-Qasem, Abeer J.;
- Alves, Carla L.;
- Ehmsen, Sidse;
- Tuttolomondo, Martina;
- Terp, Mikkel G.;
- Johansen, Lene E.;
- Vever, Henriette;
- Hoeg, Luna V. A.;
- Elias, Daniel;
- Bak, Martin;
- Ditzel, Henrik J.
Publication type:
Article
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Published in:
Cancer Communications, 2023, v. 43, n. 6, p. 720, doi. 10.1002/cac2.12425
By:
- Karimi, Leena;
- Alves, Carla L.;
- Terp, Mikkel G.;
- Tuttolomondo, Martina;
- Portman, Neil;
- Ehmsen, Sidse;
- Johansen, Lene E.;
- Bak, Martin;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Article

Found: 12